Erlotinib bulk supplier for pharma manufacturers

Erlotinib 25 mg, 100 mg, 150 mg Suppliers & Bulk Manufacturers

Available Forms: Oral Tablets

Available Strengths: 25 mg, 100 mg, 150 mg

Reference Brands: Tarceva (US & EU), Erlocip (India)

Erlotinib is a targeted oral therapy for NSCLC and pancreatic cancer, available as 25 mg, 100 mg, and 150 mg tablets in the US and EU under Tarceva® and generics.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Erlotinib Tablets are a targeted oncology treatment used in the EU and US, primarily indicated for non-small cell lung cancer (NSCLC) with EGFR mutations and advanced pancreatic cancer. As a tyrosine kinase inhibitor (TKI), Erlotinib works by inhibiting the epidermal growth factor receptor (EGFR), slowing cancer cell proliferation. Available in 25 mg, 100 mg, and 150 mg strengths, Erlotinib is marketed under the brand name Tarceva® and widely distributed as a generic formulation across global markets. Pharmaceutical distributors and B2B buyers rely on Erlotinib as a high-value, targeted therapy with well-established clinical efficacy in precision oncology.

Erlotinib — third party manufacturing & bulk supply

Erlotinib 25 mg, 100 mg, 150 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Erlotinib is supplied as Oral Tablets — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Erlotinib listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Erlotinib →

Back to Listing

Frequently Asked Questions

Erlotinib is used in the treatment of certain types of cancer, particularly non-small cell lung cancer (NSCLC) and pancreatic cancer. It is often prescribed for patients whose tumors have specific epidermal growth factor receptor (EGFR) mutations.

Erlotinib Hydrochloride is a synthetic small-molecule inhibitor that targets the epidermal growth factor receptor (EGFR) tyrosine kinase. By blocking EGFR signaling, it helps slow or stop the growth of cancer cells.

The most well-known trade name is Tarceva.

The original brand Tarceva was developed and marketed by Roche and Astellas Pharma. Many pharmaceutical companies now manufacture generic versions worldwide.

The generic name is Erlotinib Hydrochloride.

Brand names include Tarceva, Erlocip, Erlonat, and several generic versions marketed globally.

Erlotinib products are manufactured in several countries including the United States, Switzerland, India, and various EU pharmaceutical manufacturing hubs depending on the manufacturer.